Abstract
Rationale
Data on weight changes associated with Cenobamate (CNB) in patients with epilepsy is scarce. We performed a case-control study because of concern for clinically significant weight loss.
Methods
All patients exposed to CNB between its May in February 2020 until October 2023 with at least 180 days of exposure were evaluated. Baseline weight was assessed as the closest within 90 days prior to initiation of CNB. Trough and peak weights during CNB exposure and concomitant antiseizure medications (ASMs) were obtained.
Results
A total of 332 patients ...
Seguir leyendo →
15
JUN
JUN
0
